Internships at AstraZeneca

About AstraZeneca

You may wish to inform the webmaster of the site you came from that their link needs to be updated. You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. Important notice for users You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information. I have read this warning and will not be using any of the contained product information for clinical purposes. Unlocking the curative potential of cell therapy for more people with cancer In the first half we saw strong performance and continued pipeline delivery, including six key positive Phase III programmes and eight first approvals in major markets. We continue to invest at pace in our transformative technologies, and in our commercial execution to bring our innovative medicines to patients around the globe and drive growth beyond 2030.

More from AstraZeneca